Logo Image
News|Articles|June 1, 2026

Real-World Evidence in Clinical Trials: Where the Industry Stands and Where It's Headed

As the FDA formally recognizes real-world evidence as eligible confirmatory evidence for drug approval, sponsors face a growing imperative to build the data infrastructure, organizational alignment, and analytical capabilities needed to use RWE effectively across the development lifecycle.

Real-world evidence (RWE) has been moving steadily upstream in drug development. With the FDA now explicitly recognizing RWE as eligible confirmatory evidence under its updated single-trial standard, the question is no longer whether RWE belongs in clinical development, but how to build the infrastructure and organizational capabilities to use it effectively.

Related to this article

View more
© photon_photo - © photon_photo - stock.adobe.com
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
Read more
© putilov_denis - © putilov_denis - stock.adobe.com
Real-Time Clinical Trials Depend on a Scalable EHR-to-EDC Connection
Real-time clinical trials require standardized digital data capture at the point of care through scaled eSource-EDC-EHR integration, but progress stalls because competing standards lack regulatory enforcement and one-off system integrations cannot scale beyond single studies without industry-wide alignment and legal clarity on data ownership.
Read more
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
Read more
What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Read more
Where AI Governance in Clinical Development Falls Short
Where AI Governance in Clinical Development Falls Short
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, identifies three recurring failure modes in AI governance frameworks—and explains why responsible AI must be an ongoing operating discipline, not a one-time approval gate.
Read more